We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




A DNA Repair Complex Controls Antibody Class Switching

By LabMedica International staff writers
Posted on 10 Aug 2009
Researchers have dissected the Mre11-Rad50-Nbs1 (MRN) complex of DNA repair enzymes to study how the different components interact during the "gene-shuffling” process that occurs when immune B cells begin antibody production.

Investigators from the University of Michigan (Ann Arbor, USA) used advanced genetic engineering techniques to create a line of mice that lacked the genes for the entire MRN complex in B lymphocytes or that possessed an intact complex, but containing mutant Mre11 lacking DNA nuclease activity.

The scientists used these lines of mice to trace the mechanism of class switch recombination (CSR), which allows the class of antibody produced by an activated B cell to change during a process known as isotype or class switching. More...
During CSR, portions of the antibody heavy chain locus are removed from the chromosome, and the gene segments surrounding the deleted portion are rejoined to retain a functional antibody gene that produces antibody of a different isotype.

Results published in the July 26, 2009, online edition of the journal Nature Structural and Molecular Biology revealed that MRN deficiency conferred a strong defect in CSR, affecting both the classic and the alternative NHEJ (nonhomologous end joining) pathways. In contrast, absence of Mre11 nuclease activity caused a milder phenotype, revealing a separation of function within the complex.

"Class switch recombination represents a double-edged sword, being necessary for immune system function, but known to cause cancer when mistakes are made. We now understand that Mre11 and the MRN complex as a whole lie in the middle of this delicate balance,” explained senior author Dr. David O. Ferguson, assistant professor of pathology at the University of Michigan. "The link to cancer results from what is known to happen to DNA breaks at the immunoglobulin locus. On rare occasions, these special DNA breaks can recombine with distant sites in the genome, and result in chromosome translocations that cause cancer.”

Related Links:
University of Michigan




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.